SOD1 and amyotrophic lateral sclerosis: Moreover, this immunogenic region may be used for immunotherapy for SOD1-linked ALS as was reported for the SOD1 exposed dimer interface (SEDI) peptide, that is specifically exposed in monomeric SOD1 (Rakhit et al., 2007; Liu et al., 2012).